Survival of patients with high grade glioma treated with intrathecal thiotriethylenephosphoramide for ependymal or leptomeningeal gliomatosis

Timothy F Witham, Melanie B. Fukui, Carolyn Cidis Meltzer, Richard Burns, Douglas Kondziolka, Michael E. Bozik

Research output: Contribution to journalArticle

Abstract

BACKGROUND. The diagnosis of leptomeningeal dissemination of malignant glioma (meningeal gliomatosis) is associated with poor survival. Intrathecal (IT) chemotherapeutic agents used to achieve tumor control and improve survival include methotrexate, cytosine arabinoside (ara-C), thiotriethylenephosphoramide (thioTEPA), neocarzinostatin, and 3-[(4-amino-2- methyl-5-pyrimidinyl)methyl]-1-(2-chloroethyl)-1-nitrosourea hydrochloride (ACNU). Little information exists about survival following administration of IT chemotherapy. The authors report survival data from a series of patients with supratentorial anaplastic astrocytoma (AA) or glioblastoma multiforme (GBM) treated for ependymal or leptomeningeal gliomatosis with IT thio-TEPA. METHODS. The authors reviewed the records of 14 patients treated between 1991 and 1997 (GBM: n = 9; AA: n - 5). All patients were diagnosed with ependymal (n = 8) or leptomeningeal (n = 6) dissemination of tumor on the basis of clinical signs and symptoms, ependymal or leptomeningeal contrast enhancement on magnetic resonance imaging (MRI), and/or cerebrospinal fluid analysis. All 14 patients underwent placement of a ventricular reservoir system and subsequent instillation of IT thio-TEPA on a weekly basis for 6-12 weeks. Response to treatment was evaluated clinically and by MRI at intervals of 1-3 months and 3-6 months from the initiation of IT thio-TEPA. Data on survival from the time of diagnosis of dissemination was assessed. RESULTS. The median survival, from the time of diagnosis of ependymal or leptomeningeal dissemination, of patients who received IT thio-TEPA was 10 months (AA = 19 months; GBM = 10 months). Five of 14 patients had a radiographic response to treatment within 6 months. The median survival of patients with a radiographic response was 15.5 months, compared with 10 months for nonresponders. No significant neurotoxicity or myelopathy was observed. CONCLUSIONS. Early treatment with IT thio-TEPA may result in improved survival with minimal morbidity. Radiographic response may predict prolonged survival.

Original languageEnglish (US)
Pages (from-to)1347-1353
Number of pages7
JournalCancer
Volume86
Issue number7
DOIs
StatePublished - Oct 1 1999
Externally publishedYes

Fingerprint

Glioma
Triethylenephosphoramide
Survival
Astrocytoma
Glioblastoma
Cytarabine
Nimustine
Zinostatin
Magnetic Resonance Imaging
Spinal Cord Diseases
Methotrexate
Signs and Symptoms
Cerebrospinal Fluid
Neoplasms
Therapeutics
Morbidity
Drug Therapy

Keywords

  • Glioblastoma
  • Magnetic resonance imaging
  • Meningeal gliomatosis
  • Thiotriethylenephosphoramide (thio-TEPA)

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Survival of patients with high grade glioma treated with intrathecal thiotriethylenephosphoramide for ependymal or leptomeningeal gliomatosis. / Witham, Timothy F; Fukui, Melanie B.; Meltzer, Carolyn Cidis; Burns, Richard; Kondziolka, Douglas; Bozik, Michael E.

In: Cancer, Vol. 86, No. 7, 01.10.1999, p. 1347-1353.

Research output: Contribution to journalArticle

Witham, Timothy F ; Fukui, Melanie B. ; Meltzer, Carolyn Cidis ; Burns, Richard ; Kondziolka, Douglas ; Bozik, Michael E. / Survival of patients with high grade glioma treated with intrathecal thiotriethylenephosphoramide for ependymal or leptomeningeal gliomatosis. In: Cancer. 1999 ; Vol. 86, No. 7. pp. 1347-1353.
@article{1e708000f6d04d5084c472d40894d8ac,
title = "Survival of patients with high grade glioma treated with intrathecal thiotriethylenephosphoramide for ependymal or leptomeningeal gliomatosis",
abstract = "BACKGROUND. The diagnosis of leptomeningeal dissemination of malignant glioma (meningeal gliomatosis) is associated with poor survival. Intrathecal (IT) chemotherapeutic agents used to achieve tumor control and improve survival include methotrexate, cytosine arabinoside (ara-C), thiotriethylenephosphoramide (thioTEPA), neocarzinostatin, and 3-[(4-amino-2- methyl-5-pyrimidinyl)methyl]-1-(2-chloroethyl)-1-nitrosourea hydrochloride (ACNU). Little information exists about survival following administration of IT chemotherapy. The authors report survival data from a series of patients with supratentorial anaplastic astrocytoma (AA) or glioblastoma multiforme (GBM) treated for ependymal or leptomeningeal gliomatosis with IT thio-TEPA. METHODS. The authors reviewed the records of 14 patients treated between 1991 and 1997 (GBM: n = 9; AA: n - 5). All patients were diagnosed with ependymal (n = 8) or leptomeningeal (n = 6) dissemination of tumor on the basis of clinical signs and symptoms, ependymal or leptomeningeal contrast enhancement on magnetic resonance imaging (MRI), and/or cerebrospinal fluid analysis. All 14 patients underwent placement of a ventricular reservoir system and subsequent instillation of IT thio-TEPA on a weekly basis for 6-12 weeks. Response to treatment was evaluated clinically and by MRI at intervals of 1-3 months and 3-6 months from the initiation of IT thio-TEPA. Data on survival from the time of diagnosis of dissemination was assessed. RESULTS. The median survival, from the time of diagnosis of ependymal or leptomeningeal dissemination, of patients who received IT thio-TEPA was 10 months (AA = 19 months; GBM = 10 months). Five of 14 patients had a radiographic response to treatment within 6 months. The median survival of patients with a radiographic response was 15.5 months, compared with 10 months for nonresponders. No significant neurotoxicity or myelopathy was observed. CONCLUSIONS. Early treatment with IT thio-TEPA may result in improved survival with minimal morbidity. Radiographic response may predict prolonged survival.",
keywords = "Glioblastoma, Magnetic resonance imaging, Meningeal gliomatosis, Thiotriethylenephosphoramide (thio-TEPA)",
author = "Witham, {Timothy F} and Fukui, {Melanie B.} and Meltzer, {Carolyn Cidis} and Richard Burns and Douglas Kondziolka and Bozik, {Michael E.}",
year = "1999",
month = "10",
day = "1",
doi = "10.1002/(SICI)1097-0142(19991001)86:7<1347::AID-CNCR34>3.0.CO;2-M",
language = "English (US)",
volume = "86",
pages = "1347--1353",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "7",

}

TY - JOUR

T1 - Survival of patients with high grade glioma treated with intrathecal thiotriethylenephosphoramide for ependymal or leptomeningeal gliomatosis

AU - Witham, Timothy F

AU - Fukui, Melanie B.

AU - Meltzer, Carolyn Cidis

AU - Burns, Richard

AU - Kondziolka, Douglas

AU - Bozik, Michael E.

PY - 1999/10/1

Y1 - 1999/10/1

N2 - BACKGROUND. The diagnosis of leptomeningeal dissemination of malignant glioma (meningeal gliomatosis) is associated with poor survival. Intrathecal (IT) chemotherapeutic agents used to achieve tumor control and improve survival include methotrexate, cytosine arabinoside (ara-C), thiotriethylenephosphoramide (thioTEPA), neocarzinostatin, and 3-[(4-amino-2- methyl-5-pyrimidinyl)methyl]-1-(2-chloroethyl)-1-nitrosourea hydrochloride (ACNU). Little information exists about survival following administration of IT chemotherapy. The authors report survival data from a series of patients with supratentorial anaplastic astrocytoma (AA) or glioblastoma multiforme (GBM) treated for ependymal or leptomeningeal gliomatosis with IT thio-TEPA. METHODS. The authors reviewed the records of 14 patients treated between 1991 and 1997 (GBM: n = 9; AA: n - 5). All patients were diagnosed with ependymal (n = 8) or leptomeningeal (n = 6) dissemination of tumor on the basis of clinical signs and symptoms, ependymal or leptomeningeal contrast enhancement on magnetic resonance imaging (MRI), and/or cerebrospinal fluid analysis. All 14 patients underwent placement of a ventricular reservoir system and subsequent instillation of IT thio-TEPA on a weekly basis for 6-12 weeks. Response to treatment was evaluated clinically and by MRI at intervals of 1-3 months and 3-6 months from the initiation of IT thio-TEPA. Data on survival from the time of diagnosis of dissemination was assessed. RESULTS. The median survival, from the time of diagnosis of ependymal or leptomeningeal dissemination, of patients who received IT thio-TEPA was 10 months (AA = 19 months; GBM = 10 months). Five of 14 patients had a radiographic response to treatment within 6 months. The median survival of patients with a radiographic response was 15.5 months, compared with 10 months for nonresponders. No significant neurotoxicity or myelopathy was observed. CONCLUSIONS. Early treatment with IT thio-TEPA may result in improved survival with minimal morbidity. Radiographic response may predict prolonged survival.

AB - BACKGROUND. The diagnosis of leptomeningeal dissemination of malignant glioma (meningeal gliomatosis) is associated with poor survival. Intrathecal (IT) chemotherapeutic agents used to achieve tumor control and improve survival include methotrexate, cytosine arabinoside (ara-C), thiotriethylenephosphoramide (thioTEPA), neocarzinostatin, and 3-[(4-amino-2- methyl-5-pyrimidinyl)methyl]-1-(2-chloroethyl)-1-nitrosourea hydrochloride (ACNU). Little information exists about survival following administration of IT chemotherapy. The authors report survival data from a series of patients with supratentorial anaplastic astrocytoma (AA) or glioblastoma multiforme (GBM) treated for ependymal or leptomeningeal gliomatosis with IT thio-TEPA. METHODS. The authors reviewed the records of 14 patients treated between 1991 and 1997 (GBM: n = 9; AA: n - 5). All patients were diagnosed with ependymal (n = 8) or leptomeningeal (n = 6) dissemination of tumor on the basis of clinical signs and symptoms, ependymal or leptomeningeal contrast enhancement on magnetic resonance imaging (MRI), and/or cerebrospinal fluid analysis. All 14 patients underwent placement of a ventricular reservoir system and subsequent instillation of IT thio-TEPA on a weekly basis for 6-12 weeks. Response to treatment was evaluated clinically and by MRI at intervals of 1-3 months and 3-6 months from the initiation of IT thio-TEPA. Data on survival from the time of diagnosis of dissemination was assessed. RESULTS. The median survival, from the time of diagnosis of ependymal or leptomeningeal dissemination, of patients who received IT thio-TEPA was 10 months (AA = 19 months; GBM = 10 months). Five of 14 patients had a radiographic response to treatment within 6 months. The median survival of patients with a radiographic response was 15.5 months, compared with 10 months for nonresponders. No significant neurotoxicity or myelopathy was observed. CONCLUSIONS. Early treatment with IT thio-TEPA may result in improved survival with minimal morbidity. Radiographic response may predict prolonged survival.

KW - Glioblastoma

KW - Magnetic resonance imaging

KW - Meningeal gliomatosis

KW - Thiotriethylenephosphoramide (thio-TEPA)

UR - http://www.scopus.com/inward/record.url?scp=0033214593&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033214593&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1097-0142(19991001)86:7<1347::AID-CNCR34>3.0.CO;2-M

DO - 10.1002/(SICI)1097-0142(19991001)86:7<1347::AID-CNCR34>3.0.CO;2-M

M3 - Article

C2 - 10506724

AN - SCOPUS:0033214593

VL - 86

SP - 1347

EP - 1353

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 7

ER -